1H-Imidazol-2-amine, N-(2-bromo-6-fluorophenyl)-4,5-dihydro-, monohydrochloride:Exports & Compliance White Paper 2026

I. Executive Summary

Romifidine hydrochloride (CAS 65896-14-2) is a veterinary α2-adrenoceptor agonist supplied as an active pharmaceutical ingredient for prescription animal medicines, principally equine and large-animal sedation and analgesia. Chemically it is N-(2-bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine hydrochloride (C9H9BrFN3·HCl, MW ≈ 294.6), an aryl-imidazoline related to detomidine, medetomidine and xylazine. The imidazoline nitrogen is strongly basic and is isolated as a hydrochloride salt to give a water-soluble, crystallisable solid suited to injectable formulation. This is a prescription veterinary API: not a human medicine, not a research reagent, not a consumer product.

Two regulatory systems dominate. The first is veterinary pharmaceutical regulation: in the EU, Regulation (EU) 2019/6 with EMA and CVMP oversight, EU GMP Part II (ICH Q7) for the active substance, and maximum residue limits under Regulation (EC) No 470/2009 and the Commission MRL table; in the United States, FDA Center for Veterinary Medicine oversight of approved new animal drug applications, establishment registration and cGMP. The second is sports-animal control: α2-agonists are controlled medications in equestrian and racing jurisdictions, with detection times and screening that make residue control a commercial as well as legal issue.

Commercially, the material is a low-volume, high-potency, high-documentation API. Buyers are licensed veterinary manufacturers and their qualified CDMOs, purchasing against an active substance master file, a GMP certificate and an inspection history. Differentiation rests on the aryl-imidazoline impurity spectrum, on control of the aromatic amine and isothiocyanate residuals that carry mutagenic alerts, on salt stoichiometry and water content, and on a documented occupational exposure band appropriate to a compound active at microgram-per-kilogram dose levels. The guidance below is written for those counterparties and contains no human-use information.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

The API is a white to off-white crystalline hydrochloride salt, water-soluble and soluble in lower alcohols, with the imidazoline amidine conferring high basicity and a salt-dependent solubility profile. The two ortho halogens are not decorative: ortho substitution restricts rotation about the aryl-nitrogen bond and shapes receptor fit, so the regioisomeric purity of the arylamine feeds directly into pharmacological consistency. Formulation developers value the salt because an aqueous injectable presentation demands defined solubility, pH and stability behaviour, and because the potency of the class makes assay accuracy and content uniformity a patient-safety issue as much as a specification issue. Agonist activity at α2-adrenoceptors produces dose-dependent sedation, analgesia and muscle relaxation in target species, with cardiovascular effects that drive prescription-only control.

• Aryl-Imidazoline (Cyclic Amidine) Core: The 4,5-dihydro-1H-imidazol-2-amine unit is the pharmacophore shared with detomidine, medetomidine and clonidine-class agents. Its basicity governs salt formation and crystallisation, and its ring is susceptible to hydrolytic opening, making the ring-opened guanidine a routine specified degradation product.
• 2-Bromo-6-fluoroaryl Substitution: Ortho halogen placement controls conformation and receptor selectivity and defines the impurity profile: des-bromo, des-fluoro and regioisomeric species from the arylamine synthesis are the related substances a specification must name and limit.

2.2 Synthesis and Manufacturing Technologies

Published and industrial approaches converge on a common logic: build the substituted aniline, activate it as an isothiocyanate, cyanamide or equivalent electrophile, condense with ethylenediamine and close the ring, then form the hydrochloride salt. Alternatives displace a leaving group from a preformed 2-substituted imidazoline with the arylamine. The arylamine itself comes from electrophilic bromination of a fluorinated aniline, where regioselectivity between positions ortho and para to the amine drives the isomer burden. Reagent choices, stoichiometry and cycle times are route-specific and are not discussed here.

• Ring-Closure Strategy and Reagent Selection: Classical cyclodesulfurisation of the thiourea intermediate uses mercury or heavy-metal promoters, introducing ICH Q3D elemental risk and a Minamata-related sustainability problem. Modern routes prefer oxidative or carbodiimide-mediated closure with non-mercury reagents.
• Salt Formation and Solid-State Control: The final step sets stoichiometry, counter-ion and water content and crystal form. Controlled hydrogen chloride addition in an alcohol or alcohol-ether system, followed by crystallisation and low-temperature drying, delivers reproducible assay, defined water content and a stable solid form.

2.3 Core Application Matrix

• Equine and Large-Animal Sedation and Analgesia: The principal commercial use is in injectable prescription products for horses and other large animals, where α2-agonist sedation supports examination, diagnostic imaging, minor procedures and premedication. Demand tracks veterinary practice volumes and the approved product portfolio in each market.
• Combination and Premedication Regimens: Combination use with other agents is a formulation and labelling matter for the marketing-authorisation holder. API supplied for such products must meet the same GMP, stability and residue-data expectations, with change control coordinated with the authorisation.
• Analytical Standards and Residue Method Development: Characterised API and its related substances support quality-control method validation, stability-indicating testing and the development of residue and anti-doping screening methods used by control laboratories.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand is driven by equine and large-animal practice, by the shift toward standing procedures requiring reliable sedation, and by replacement of older regimens with agents having defined detection times. Generic competition among α2-agonists pressures formulation margins, which pushes marketing-authorisation holders to qualify lower-cost API sources, while consolidation among veterinary pharmaceutical groups concentrates purchasing and raises qualification standards. Regulatory tightening on residues in food-producing animals simultaneously narrows which species claims are commercially viable.

3.2 Capacity Distribution and Export Flows

Capacity follows veterinary API chemistry rather than bulk commodity chemistry. Chinese producers in Jiangsu, Shandong and Zhejiang supply imidazoline and halogenated-aniline capacity at scale, serving domestic formulators and export customers. Indian manufacturers around Ahmedabad, Hyderabad and Mumbai combine the same chemistry with EU GMP certificates and FDA-facing documentation, often as second sources for marketing-authorisation holders. European sites in Germany, Italy and the Netherlands retain originator-linked, high-containment capacity. Finished-product manufacturing and API import therefore often sit in different regions, making the API dossier the hinge of the trade.

3.3 Market Bifurcation and Pricing Dynamics

The market divides into dossier-supported veterinary GMP supply and loosely specified material, and the spread reflects documentation and containment rather than synthesis difficulty. Qualified supply carries an active substance master file, validation batches, stability commitments, residue data support and audit readiness. Costs move with brominated and fluorinated intermediates, solvent inputs, and the containment and cleaning overhead a low exposure limit imposes. Buyers should expect lead times to reflect shared-suite campaign scheduling, not merely reactor availability, and currency movements plus brominated intermediate availability add short-term price volatility, so multi-year agreements with price-adjustment mechanisms are common in this segment.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

Veterinary API compliance is species-specific in a way human API compliance is not: the same molecule may be usable in a non-food animal and unusable in a food-producing animal, or usable only with a long withdrawal period, depending on whether a maximum residue limit exists. Exporters must understand the intended species claim of the customer's finished product.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• Regulation (EU) 2019/6 and MRL or Withdrawal Determination: Veterinary medicinal products are authorised under Regulation (EU) 2019/6 with CVMP assessment, and substances used in food-producing animals require a maximum residue limit under Regulation (EC) No 470/2009 and the Commission MRL table. For equidae, substances without an established entry fall back on the equine list and its default withdrawal period, restricting use to animals declared non-food-producing. Exporters should confirm the intended species claim before accepting an order.
• EU GMP Part II, ASMF and REACH or CLP: Active substances must be made to EU GMP Part II (ICH Q7), supported by an active substance master file, with third-country imports requiring written confirmation of GMP equivalence. Separately, EU placement is subject to REACH registration and CLP classification, and α2-agonist safety data sheets commonly carry acute toxicity and aquatic hazard statements that drive labelling and transport classification.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• FDA CVM Approval and Establishment Obligations: In the United States, α2-agonist sedatives for animals are approved new animal drugs; API supply supports an approved or abbreviated application, with the manufacturer registered and listed under cGMP. Compounding from bulk active substance is separately constrained by CVM guidance on bulk drug substances, so exporters should confirm that a customer's intended use is lawful.
• TSCA Commercial Status and Environmental Review: Commercial import requires the substance to be on the TSCA inventory or covered by an exemption, certified at entry. Halogenated aromatic and amine-bearing process streams also attract scrutiny of effluent characterisation, and environmental assessment of the finished product covers excretion and environmental fate of the active substance.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Sustainability pressure concentrates in three places: halogenated aromatic waste, metal reagents used in ring closure, and solvent intensity in salt formation and purification. Customers and regulators increasingly ask for documented disposal routes for brominated and fluorinated streams and a credible mercury-avoidance position, an ICH Q3D and Minamata concern. Halogenated aromatics also raise persistence and bioaccumulation questions in receiving waters, which is why treatment performance data is increasingly requested alongside disposal documentation.

5.1 Carbon Footprint and Circular Economy

Energy intensity is driven by solvent recovery, crystallisation, drying and the HVAC load of contained suites. Levers are heat-pumped solvent recovery, solvent substitution reducing halogenated make-up, and campaign scheduling that minimises requalification. Reporting Scope 1 and 2 emissions with energy intensity per kilogram, and Scope 3 for intermediates and waste treatment, is becoming standard in supplier questionnaires.

5.2 Sustainable Sourcing and Traceability

Traceability runs from the halogenated starting material to the sealed drum, and matters for two reasons: the impurity profile is inherited from the arylamine, and a change of starting-material supplier is a regulatory variation. Lot-level records linking starting material, process batches, validation status and dispatch documents, retained for the GMP retention period, make investigations tractable, and buyers increasingly audit them.

VI. Supply Chain Resilience and Export Logistics

Logistics is governed by potency and moisture sensitivity rather than temperature. The salt is stable at controlled ambient conditions but hygroscopic in handling, and consignments are high-value and may be subject to dangerous-goods rules. Packaging must combine a moisture barrier with UN-certified construction where required, and documentation must travel with the goods.

6.1 Packaging Standards and Moisture/Contamination Control

• Moisture-Barrier Primary Containment: Standard practice is double polyethylene liners with desiccant inside a lined fibre or HDPE drum, closed under controlled humidity and sealed with tamper-evident, numbered closures. Water uptake during storage drives assay drift and caking, and is the most common cause of out-of-specification water content at destination.
• Segregation, Labelling and Secondary Packaging: Potent veterinary actives are segregated from food, feed and human pharmaceutical stocks, labelled as veterinary prescription API with the applicable GHS pictograms, and shipped with the certificate of analysis, GMP statement and, where relevant, the dangerous-goods declaration matched to the pack.

6.2 Dangerous Goods Identification and Transit Protocols

Safety data sheets for α2-agonist salts commonly carry acute toxicity and chronic aquatic hazard statements, and where the classification meets dangerous-goods thresholds the consignment moves as a Class 6.1 toxic solid under an organic-toxic n.o.s. entry with UN-certified packaging and full declaration under IMDG, ADR and IATA. Classification must be confirmed against the current SDS for the grade and pack size before booking. Protocol: verify the SDS, use UN-certified packaging where required, avoid consolidation with food or feed cargo, and require carriers to report seal breakage. Where the consignment is not classified, shippers should still keep the SDS and the classification rationale on file, because customers and inspectors routinely request it.

VII. Enterprise Global Expansion Strategy Guide

Winning veterinary API programmes requires dossier readiness, residue literacy and containment discipline. Producers that qualified did three things: they built the master file before the customer needed it, they understood the species and residue implications of the finished product, and they engineered to a documented exposure limit. Containment also determines which customers can be served at all, since several marketing-authorisation holders now refuse to qualify a site without a documented OEB design.

1. Build the Veterinary Dossier and Support Residue Data: Open and maintain an active substance master file, support the customer's MRL or withdrawal-period position with residue data where required, and offer letters of access with change-control notification. Dossier ownership converts a commodity quote into a qualified position.
2. Engineer Containment to a Documented Exposure Limit: Derive an HBEL or PDE, assign an OEB band and build closed charging, isolator transfer, dedicated or campaign-cleaned equipment and cleaning validation to limits calculated from it, supported by exposure monitoring.
3. Qualify the Impurity and Species-Control Package: Provide standards and validated methods for regioisomeric and dehalogenated impurities, ICH M7 control of the aromatic amine and cyclisation reagents, Q3C and Q3D datasets, confirmed stoichiometry and water content, and stability data on commercial packs, stating the material is for licensed veterinary manufacture only.

VIII. Conclusion

Romifidine hydrochloride is a potent veterinary API whose export economics are set by dossiers, residue rules and containment rather than synthesis difficulty. Demand will follow equine and large-animal practice and the portfolios of marketing-authorisation holders, while value accrues to producers holding an active substance master file, a GMP inspection history, clean elemental and mutagenic-impurity positions and a documented OEB design. Price-only producers remain confined to unqualified work.

For buyers and compliance officers the discipline is to qualify only licensed veterinary manufacturers, confirm the species claim and residue position before ordering, demand regioisomer and mutagenic-impurity specificity, and require lot traceability from halogenated starting material to sealed drum. Because α2-agonists are controlled medications in equestrian and racing jurisdictions, buyers should expect questions from sports-control authorities and keep distribution records. This paper is a B2B overview for professionals and contains no human-use guidance.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global Romifidine hydrochloride Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global Romifidine hydrochloride supply chain:

• China — Scaled Imidazoline and Halogenated Aniline Capacity: Producers in Jiangsu, Shandong and Zhejiang combine selective bromination of fluorinated anilines with imidazoline ring-closure and salt-formation plant. Strengths are cost, scale and speed; recurring gaps are master file maturity and EU or FDA veterinary inspection experience.
• India — Veterinary API and Dossier Ecosystem: Manufacturers around Ahmedabad, Hyderabad and Mumbai pair the same chemistry with EU GMP certificates, master files and regulatory support, making them the natural second source for marketing-authorisation holders. Their constraint is dependence on imported halogenated intermediates.
• European Union — Originator-Linked and Contained Capacity: German, Italian and Dutch sites hold the premium tier, tied to innovator veterinary supply chains, with high-containment suites, established CVMP dossiers and residue expertise. Volumes are smaller and costs higher, but these sites set the benchmark others are audited against.